Repare Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Repare Therapeutics (NASDAQ:RPTX) Second Quarter 2025 Results

Key Financial Results

• Net loss: US$16.7m (loss narrowed by 52% from 2Q 2024).
• US$0.39 loss per share (improved from US$0.82 loss in 2Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Repare Therapeutics EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 85%. Earnings per share (EPS) exceeded analyst estimates by 30%.

Looking ahead, revenue is expected to decline by 23% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 19%.

Performance of the American Biotechs industry.

The company's shares are up 2.3% from a week ago.

Risk Analysis

Be aware that Repare Therapeutics is showing 5 warning signs in our investment analysis and 3 of those are significant...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.